Clinical trials
Tardive Dyskinesia trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
31 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 1 |
| 2011 | 2 |
| 2012 | 2 |
| 2013 | 1 |
| 2014 | 5 |
| 2015 | 2 |
| 2016 | 1 |
| 2017 | 2 |
| 2018 | 2 |
| 2019 | 2 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 3 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 21 |
| Recruiting | 4 |
| Withdrawn | 3 |
| Unknown status | 2 |
| Not yet recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Neurocrine Biosciences | 12 |
| Auspex Pharmaceuticals, Inc. | 3 |
| Yale University | 2 |
| Caroff, Stanley N., M.D. | 1 |
| Corporal Michael J. Crescenz VA Medical Center | 1 |
| Emory University | 1 |
| Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | 1 |
| Joseph Jankovic | 1 |
| Northwell Health | 1 |
| Power Life Sciences Inc. | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Tardive Dyskinesia | 31 |
| Movement Disorders | 7 |
| Schizophrenia | 6 |
| Dyskinesias | 4 |
| Neurologic Manifestations | 4 |
| Psychotic Disorders | 4 |
| Signs and Symptoms | 4 |
| Central Nervous System Diseases | 3 |
| Intellectual Disability | 3 |
| Nervous System Diseases | 3 |
Trials
Showing 1 to 25 of 31. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.